Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
In this study, the amino acid arginine (ARG) and P-glycoprotein (P-gp) inhibitors verapamil hydrochloride (VER), piperine (PIP) and quercetin (QRT) were used as co-formers for co-amorphous mixtures of a Biopharmaceutics classification system (BCS) class IV drug, furosemide (FUR). FUR mixtures with V...
Saved in:
Main Authors: | Marika Ruponen (Author), Konsta Kettunen (Author), Monica Santiago Pires (Author), Riikka Laitinen (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of Candesartan Cilexetil-L-Arginine Co-amorphous Formation and Its Solubility Test
by: Fikri Alatas, et al.
Published: (2022) -
Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs
by: Yusuke Kono, et al.
Published: (2021) -
Development and Characterization of an Amorphous Solid Dispersion of Furosemide in the Form of a Sublingual Bioadhesive Film to Enhance Bioavailability
by: Viviana De Caro, et al.
Published: (2017) -
Co-administration of herbal inhibitors of P-glycoprotein with renal drugs enhance their bioavailability- In silico approach
by: Chandana Roy, et al.
Published: (2023) -
Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies
by: Jingwen Liu, et al.
Published: (2021)